Previous studies have shown that NGF can reverse axonal degeneration, demyelination, and atrophy in diabetic neuropathy, and the efficacy of recombinant human NGF (rhNGF) has been tested in a phase III trial of patients with diabetic neuropathy [120]. Here, NGF is linked to diabetic neuropathy.